Effectiveness of ICI-ICI versus ICI-TKI combinations in patients with IMDC intermediate- and poor-risk metastatic renal cell carcinoma: a sub-analysis of the MEET-URO 33 study

No statistically significant differences in survival or response were observed between ICI-ICI and ICI-TKI combinations in patients with IMDC intermediate- and poor-risk mRCC.

Authors

Institutions

Publication Details

Journal
Cancer Immunology Immunotherapy
Published
2026-02-03
DOI
https://doi.org/10.1007/s00262-026-04318-x
Primary Topic
Renal cell carcinoma treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Effectiveness of ICI-ICI versus ICI-TKI combinations in patients with IMDC intermediate- and poor-risk metastatic renal cell carcinoma: a sub-analysis of the MEET-URO 33 study

Lucia Bonomi, Silvia Zai, Filippo Maria Deppieri, Francesca Vignani et al.
Cancer Immunology Immunotherapy
Renal cell carcinoma treatment
article

Effectiveness of ICI-ICI versus ICI-TKI combinations in patients with IMDC intermediate- and poor-risk metastatic renal cell carcinoma: a sub-analysis of the MEET-URO 33 study

Lucia Bonomi, Silvia Zai, Filippo Maria Deppieri, Francesca Vignani, E. Verzoni, Cristian Lolli, Emanuela Fantinel, Francesca Bertolotti, Paolo Andrea Zucali, Alessandro Acunzo, Eleonora Lai, Alessia Mennitto, Annalisa Guida, Mariella Sorarù, Alessio Signori, Sebastiano Buti, Vincenza Conteduca, Giuseppe Fornarini, Giandomenico Roviello, Sarah Scagliarini, Cecilia Nasso, Pasquale Rescigno, Giuseppe Luigi Banna, Michele Maffezzoli, Alessia Cavo, Laura Lombardo, Andrea Di Marco, Davide Bimbatti, Brigida Anna Maiorano, Roberto Filippi, Cristina Masini, Marcello Tucci, Silvia Chiellino, Luigi Formisano, Roberto Iacovelli, Alberto Dalla Volta, Michela Bosoni, Marilena Di Napoli, Claudia Caserta, Sara Elena Rebuzzi, Carlo Messina
article en

Abstract

No statistically significant differences in survival or response were observed between ICI-ICI and ICI-TKI combinations in patients with IMDC intermediate- and poor-risk mRCC.

Cancer Immunology ImmunotherapyVol. 75(3)
University of Foggia (IT), University of Verona (IT), Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT), University of Parma (IT), University of Udine (IT), Humanitas University (IT), Vita-Salute San Raffaele University (IT), Santa Maria Nuova Hospital (IT), Fondazione Roma (IT), Agostino Gemelli University Polyclinic (IT), Ospedale San Paolo (IT), Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT), Ospedale Antonio Cardarelli (IT), Portsmouth Hospitals NHS Trust (GB), Azienda Sanitaria Unità Locale di Reggio Emilia (IT), Ospedali Riuniti di Foggia (IT), Azienda Ospedaliera Universitaria Integrata Verona (IT), Istituto Ramazzini (IT), Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT), Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT), Ospedale Papa Giovanni XXIII (IT), Istituto Oncologico Veneto (IT), Azienda Sanitaria Locale di Asti (IT), Ospedale Santa Maria (IT), Azienda Ospedaliero Universitaria Maggiore della Carita (IT), A. O. Ordine Mauriziano di Torino (IT), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT), Azienda Ospedaliera Ospedale Maggiore (IT), Azienda di Rilievo Nazionale ed Alta Specializzazione (IT), Ospedale Policlinico San Martino (IT), Candiolo Cancer Institute (IT), Policlinico San Matteo Fondazione (IT), Ospedale San Bortolo (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo (IT), Villa Torri Hospital (IT), IRCCS Humanitas Research Hospital (IT), Ospedale Santa Corona (IT), Hospital of Prato (IT), Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT), University of Florence (IT), University of Portsmouth (GB), Misericordia University (US), University of Naples Federico II (IT), University of Brescia (IT), University of Genoa (IT), Newcastle University (GB)
No poverty
Openalex Percentile: Top 69%
Renal cell carcinoma treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.